Kindly make notes for MD Anaesthesiology exam notes on surviving sepsis guidelines latest 2026
Checking Date & Time
Reading File
Finding Sources
Searching PubMed
"surviving sepsis campaign" AND "guidelines"
Searching the Web
Surviving Sepsis Campaign guidelines 2025 2026 update latest recommendations
Excellent — the SSC 2026 guidelines are now published. Let me get the detailed content simultaneously.
Reading File
Reading Article
PMID: 41869844
Searching the Web
SSC 2026 surviving sepsis campaign adult guidelines full recommendations septic shock management
Searching the Web
SSC 2026 surviving sepsis campaign 129 statements full list antimicrobials vasopressors corticosteroids fluid resuscitation ventilation
Finding Sources
Searching the Web
site:criticalcarescience.org OR site:emcrit.org SSC 2026 sepsis guidelines detailed recommendations antibiotics blood cultures lactate MAP targets
Finding Sources
Searching the Web
"2026 surviving sepsis" new recommendations antibiotic timing steroids hydrocortisone vitamin C thiamine vasopressin angiotensin
Reading File
Searching the Web
pulmonologyadvisor SSC 2026 surviving sepsis guidelines full update key changes steroids pressor fluid de-escalation rehabilitation
Reading File
I now have sufficient information. Let me compile the comprehensive exam notes.---
🧠 MD Anaesthesiology Exam Notes
Surviving Sepsis Campaign (SSC) Guidelines — 2026 Update
Source: SSC 2026 Adult Guidelines (published simultaneously in Intensive Care Medicine and Critical Care Medicine, March 2026) — 129 statements total, 46 new statements not previously addressed. Also referenced: SSC 2021, Miller's Anaesthesia 10e, Schwartz's Surgery 11e, Harrison's 22e.
1. DEFINITIONS (Sepsis-3, carried forward)
| Term | Definition |
|---|---|
| Sepsis | Life-threatening organ dysfunction caused by a dysregulated host response to infection. SOFA score ≥ 2 points above baseline |
| Septic Shock | Sepsis + vasopressor requirement to maintain MAP ≥ 65 mmHg + serum lactate > 2 mmol/L despite adequate fluid resuscitation |
| qSOFA (screening) | ≥ 2 of: altered mentation, RR ≥ 22/min, SBP ≤ 100 mmHg |
Exam tip: Septic shock mortality > 40%. Requires both vasopressor need + elevated lactate to distinguish from sepsis alone.
2. EARLY RECOGNITION & SCREENING (New in 2026)
- Standardized screening tools should be used in the prehospital setting (new 2026 emphasis)
- Immediate assessment of likelihood of infectious vs. non-infectious cause of organ dysfunction
- Lactate measurement recommended as part of initial workup
- Prehospital: initiate screening and early notification to receiving hospital
3. BLOOD CULTURES & DIAGNOSTICS
| Recommendation | Strength |
|---|---|
| Obtain blood cultures before antimicrobials | Strong / Good practice |
| Obtain cultures from multiple sites (peripheral + central) | Strong (new 2026, based on single-site sampling SR) |
| Do not delay antimicrobials if cultures cannot be obtained promptly | Strong |
| Imaging to confirm infection source as rapidly as possible | Good practice |
| Serial procalcitonin to guide antibiotic de-escalation | Conditional |
4. ANTIMICROBIAL THERAPY (Major 2026 Updates)
Timing
| Clinical Scenario | Recommendation | Strength |
|---|---|---|
| Possible, probable, or definite septic shock | Antimicrobials immediately, ideally within 1 hour | Strong, very low evidence |
| Probable or definite sepsis without shock | Antimicrobials immediately, ideally within 1 hour | Strong, very low evidence |
| Possible sepsis without shock | Time-limited rapid investigation; if concern persists → antimicrobials within 3 hours | Conditional, very low evidence |
| Clinicians should assess likelihood of infection before antibiotics | — | Good practice |
Antibiotic Selection
- Broad-spectrum empirical therapy covering likely pathogens
- Consider local resistance patterns (antibiogram)
- Combination therapy (e.g., beta-lactam + aminoglycoside/fluoroquinolone) for high-risk/immunocompromised
- Reassess daily — de-escalate as soon as cultures/sensitivities available
- Duration: 7–10 days for most infections; shorter courses appropriate for many patients
Antifungals
- Empirical antifungals suggested in patients at high risk for Candida (prolonged antibiotics, immunosuppression, abdominal surgery, TPN)
5. SOURCE CONTROL
- Identify anatomic site of infection as rapidly as possible
- Source control within 6–12 hours of diagnosis (ideally)
- Preferred: least invasive effective intervention (e.g., percutaneous drainage > open surgery)
- Remove potentially infected intravascular devices (central lines, etc.)
- Re-look if patient fails to improve despite appropriate antibiotics
6. INITIAL RESUSCITATION (2026 Updates)
Fluid Resuscitation
| Recommendation | Detail | Strength |
|---|---|---|
| ≥ 30 mL/kg IV crystalloid in first 3 hours for sepsis-induced hypoperfusion or septic shock | Use actual body weight; for BMI > 30, use adjusted/ideal body weight | Conditional |
| Ongoing fluid guided by dynamic assessment | HR, BP, urine output, dynamic indices (PPV, SVV, PLR) | Good practice |
| Clinicians should reassess frequently | Avoid both under- and over-resuscitation | Good practice |
| Fluid removal after stabilization (de-resuscitation) | NEW 2026 — active de-resuscitation/diuresis once patient stabilized | New statement |
Fluid Type
| Fluid | Recommendation |
|---|---|
| Balanced crystalloids (e.g., lactated Ringer's, Plasmalyte) | Preferred over normal saline (lower risk of hyperchloraemic acidosis and AKI) |
| Albumin | Suggested as adjunct if large volumes of crystalloid required |
| Hydroxyethyl starch (HES) | Do NOT use — associated with AKI and mortality |
| Gelatin-based fluids | Do NOT use |
| 0.9% Normal saline | Avoid as primary fluid; acceptable if balanced crystalloids unavailable |
Resuscitation Goals / Endpoints
- MAP ≥ 65 mmHg
- Urine output ≥ 0.5 mL/kg/hr
- Normalize lactate (lactate clearance ≥ 10% every 2 hours)
- ScvO₂ ≥ 70% (MvO₂ ≥ 65%)
- Clinical improvement: mental status, skin perfusion
Exam tip — 2026 change: CVP is not a recommended resuscitation endpoint. Dynamic parameters (PLR, PPV, SVV, echocardiography) preferred.
7. VASOPRESSORS (2026 Updates)
Choice of Vasopressor
| Agent | Role | Dose |
|---|---|---|
| Norepinephrine | First-line vasopressor | Start 0.01–0.5 mcg/kg/min; titrate to MAP ≥ 65 |
| Vasopressin | Add-on to NE to raise MAP or reduce NE dose | 0.01–0.03 units/min (fixed dose) |
| Epinephrine | Alternative if NE + vasopressin insufficient | — |
| Dopamine | Only in select patients (low tachy/arrhythmia risk) — NOT for renal protection | — |
| Phenylephrine | Not recommended (reflex bradycardia, reduces CO) | — |
| Angiotensin II | Consider for refractory vasodilatory shock (conditional) | — |
Vasopressor Timing (New 2026)
- For sepsis-induced hypotension: suggest initiating vasopressor at the same time as fluid resuscitation rather than waiting for fluid loading to complete
- Peripheral IV administration of vasopressors is acceptable for initial management (new guidance) — do not delay for central access
MAP Target
| Population | Target MAP |
|---|---|
| Standard adults | 65 mmHg — strong recommendation |
| Older adults (≥ 65 years) | NEW 2026: May target lower MAP (60–65 mmHg) — reduces vasopressor exposure in elderly |
Exam tip: MAP 65 remains the primary target. Permissive hypotension (MAP 60–65) does not appear better than standard care in general population (SEPSISPAM trial).
Inotropes
- Dobutamine: Add when there is evidence of myocardial dysfunction with hypoperfusion despite adequate preload and MAP
- Levosimendan: Not routinely recommended
8. CORTICOSTEROIDS (2026 Update)
| Recommendation | Detail | Strength |
|---|---|---|
| IV Hydrocortisone | For septic shock when haemodynamic stability not achieved despite adequate fluids + vasopressors | Conditional |
| Dose | 200 mg/day continuous infusion (preferred over boluses) | — |
| Duration | Until vasopressors no longer needed | — |
| Dexamethasone | Not recommended as substitute (no mineralocorticoid activity) | — |
| Fludrocortisone | Consider adding if hydrocortisone alone | Optional |
| ACTH stimulation test | Not recommended to guide steroid use | Strong |
Mechanism: Steroids decrease vasopressor requirements and facilitate shock reversal. Mortality benefit remains uncertain.
9. VITAMIN C & METABOLIC THERAPIES (2026 Change)
| Agent | 2021 | 2026 |
|---|---|---|
| Vitamin C | Suggested (conditional) | Against routine use — randomised trials (VITAMINS, CITRIS-ALI, LOVIT) showed no mortality benefit |
| Thiamine (Vit B1) | No recommendation | Suggested in deficiency states |
| High-dose Vitamin B12 | — | Under investigation; no firm recommendation yet |
| Selenium | Against | Against |
| Statins | Against | Against |
Exam key point: Vitamin C is now not recommended. This is a significant 2026 reversal from earlier enthusiasm.
10. BLOOD PRODUCTS
| Product | Threshold | Recommendation |
|---|---|---|
| pRBC | Hb < 7 g/dL | Transfuse (Strong) — unless myocardial ischaemia, severe hypoxaemia, active haemorrhage |
| FFP | Not for correcting elevated INR without bleeding | — |
| Platelets (prophylactic) | < 10,000/mm³ | Transfuse |
| Platelets (if bleeding risk) | < 20,000/mm³ | Transfuse |
| Platelets (active bleeding / procedure) | < 50,000/mm³ | Transfuse |
| Erythropoietin | Not recommended | — |
11. MECHANICAL VENTILATION (Sepsis-related ARDS)
| Parameter | Recommendation | Strength |
|---|---|---|
| Tidal Volume | 6 mL/kg IBW | Strong |
| Plateau Pressure | < 30 cmH₂O | Strong |
| Driving Pressure | Target < 15 cmH₂O | Conditional |
| PEEP | Higher PEEP strategy for moderate-severe ARDS | Conditional |
| Prone Positioning | ≥ 12–16 hrs/day for PaO₂/FiO₂ < 150 | Strong |
| High-frequency oscillation (HFOV) | Against | Strong |
| Neuromuscular blockade | For early severe ARDS (P/F < 150) — short course | Conditional |
| Recruitment manoeuvres | Suggested for severe hypoxaemia; avoid sustained high-pressure RM | Conditional |
| Conservative O₂ | Target SpO₂ 92–96% (avoid hyperoxia) | Conditional |
| Weaning | Use spontaneous breathing trial (SBT) protocols | Strong |
Non-Invasive Ventilation (NIV) / HFNC
- HFNC preferred over NIV for sepsis-induced hypoxaemic respiratory failure (mild-moderate ARDS)
- If HFNC fails, intubate promptly (avoid prolonged delay)
- NIV may be tried in immunocompromised patients
12. SEDATION & ANALGESIA (Analgesia-First Approach)
| Recommendation | Detail |
|---|---|
| Analgesia first | Treat pain before sedation (analgesia-first approach) |
| Minimize sedation | Use lightest sedation level; target RASS –1 to 0 |
| Daily interruption | Spontaneous awakening trials (SAT) + SBT bundles |
| Preferred sedatives | Propofol or dexmedetomidine (over benzodiazepines) |
| Benzodiazepines | Avoid (associated with delirium, prolonged ventilation) |
| Delirium screening | Use CAM-ICU or ICDSC twice daily |
| Delirium treatment | Antipsychotics (haloperidol) — conditional; mobilization, sleep hygiene |
ABCDEF Bundle: Assess & manage pain, Both SAT & SBT, Choose right sedative, Delirium monitoring, Early mobility, Family engagement
13. GLUCOSE CONTROL
| Recommendation | Target | Strength |
|---|---|---|
| Protocolized glucose management | Upper limit < 180 mg/dL (10 mmol/L) | Strong |
| Check glucose every 1–2 hours until stable, then every 4 hours | — | Good practice |
| Avoid hypoglycaemia | Use continuous glucose monitoring as adjunct | — |
| Do NOT target tight glucose (81–108 mg/dL) | Increases hypoglycaemia risk | Strong |
14. RENAL REPLACEMENT THERAPY (RRT)
| Recommendation | Detail | Strength |
|---|---|---|
| Initiate RRT for AKI with life-threatening indications | Refractory hyperkalaemia, acidosis, fluid overload, uraemia | Strong |
| Do NOT initiate RRT based on creatinine/oliguria alone | Wait for clinical indication | Strong |
| CRRT vs. IHD | Either acceptable; CRRT preferred in haemodynamically unstable | Conditional |
| High-volume haemofiltration | Not recommended | Strong |
15. DVT PROPHYLAXIS
- Low-molecular-weight heparin (LMWH) preferred over unfractionated heparin (UFH)
- Pharmacological prophylaxis recommended unless contraindicated (active bleeding, severe thrombocytopenia)
- Add mechanical prophylaxis (sequential compression devices) when pharmacological contraindicated
16. STRESS ULCER PROPHYLAXIS
- Use proton pump inhibitor (PPI) or H₂-blocker in patients with risk factors for GI bleeding (coagulopathy, mechanical ventilation > 48 hrs, prior GI bleed)
- Not all ICU patients require prophylaxis — risk stratify
17. NUTRITION
| Recommendation | Detail | Strength |
|---|---|---|
| Early enteral nutrition | Within 48 hours of ICU admission (if haemodynamically stable) | Strong |
| Avoid early parenteral nutrition | If enteral route possible | Strong |
| Caloric target | 15–25 kcal/kg/day; increase gradually | — |
| Protein | 1.2–2 g/kg/day | — |
| Do NOT use supplemental omega-3 fatty acids, selenium, glutamine routinely | — | Conditional against |
18. POST-SEPSIS CARE (New 2026 Emphasis)
New 2026 statements specifically address the post-discharge continuum:
- Physical rehabilitation: Early mobilisation in ICU; structured physiotherapy post-discharge
- Psychological support: Screen for PTSD, depression, anxiety in survivors; referral as needed
- Cognitive rehabilitation: Assess for post-sepsis cognitive impairment
- Follow-up clinic: Dedicated post-ICU/post-sepsis follow-up within 4 weeks of discharge
- Caregiver support: Acknowledge and support family/caregiver burden
PICS (Post-Intensive Care Syndrome): Physical impairment, cognitive dysfunction, psychiatric disorders — all addressed in 2026 as a continuum of care
19. SPECIAL POPULATIONS (2026 New Sections)
Older Adults (≥ 65 years)
- Permissive MAP target 60–65 mmHg may reduce vasopressor burden
- Higher risk of fluid overload — more careful de-resuscitation
- Screening for frailty (Clinical Frailty Scale) to guide prognosis/goals of care
Immunocompromised / Neutropenic Fever
- Broader empirical antibiotics + antifungal cover
- Antibiotic timing within 1 hour regardless
- G-CSF: NOT recommended to increase neutrophil count in sepsis
Paediatric (SSC 2026 Paediatric — separate guideline, 61 statements)
- Age-appropriate MAP targets
- Fluid resuscitation: no "push" fluids for fluid-responsive without shock
- Corticosteroids: only for fluid/vasopressor-refractory shock
20. THE SSC BUNDLES (Hour-1 Bundle)
"Hour-1 Bundle" — all within 1 hour of recognition:
| Step | Action |
|---|---|
| 1 | Measure lactate (remeasure if > 2 mmol/L) |
| 2 | Obtain blood cultures before antibiotics |
| 3 | Administer broad-spectrum antibiotics |
| 4 | Begin 30 mL/kg crystalloid for hypotension or lactate ≥ 4 mmol/L |
| 5 | Apply vasopressors (norepinephrine) if MAP < 65 mmHg during/after fluids |
21. QUICK SUMMARY TABLE — KEY 2026 CHANGES vs. 2021
| Domain | 2021 | 2026 Change |
|---|---|---|
| Screening | Hospital-based | Prehospital screening added |
| Blood cultures | Before antibiotics | Multiple-site sampling (peripheral + central) |
| Antibiotic timing (possible sepsis without shock) | 3 hrs | Confirmed 3 hrs after time-limited investigation |
| Vasopressor timing | After fluids | Concurrent with fluids (no delay for central access) |
| Peripheral vasopressors | Mentioned | Explicitly endorsed for initial management |
| MAP in elderly | 65 mmHg | 60–65 mmHg acceptable |
| Fluid removal | Not addressed | Active de-resuscitation after stabilisation |
| Vitamin C | Conditional recommendation | Not recommended |
| Post-discharge rehab | Minimal | Major new section (PICS, rehabilitation, follow-up) |
| Paediatric guideline | 2020 edition | 2026 paediatric update (61 statements, 20 new) |
22. ANAESTHESIA-SPECIFIC CONSIDERATIONS
| Scenario | Key Points |
|---|---|
| Induction of anaesthesia in sepsis | Haemodynamic instability — use ketamine or etomidate (minimal cardiac depression); avoid propofol boluses |
| Etomidate | Single dose acceptable; prolonged use avoided (adrenal suppression) |
| Vasopressors peri-induction | Have norepinephrine/vasopressin ready before induction |
| Fluid loading pre-induction | Ensure adequate preload; use dynamic indices |
| Regional vs. GA | Regional preferred where feasible to avoid GA risks |
| Lung protective ventilation intra-op | 6 mL/kg IBW, PEEP 5–8, driving pressure < 15 regardless of ARDS |
| Point-of-care ultrasound (POCUS) | Evaluate LV function, IVC collapsibility, lung B-lines before/during resuscitation |
| TEG/ROTEM | Use for coagulopathy-guided blood product administration |
23. MNEMONIC — "ABCDE of Sepsis Management"
A — Airway/Antibiotics (within 1 hr) B — Blood cultures (before antibiotics) + Balanced crystalloid (30 mL/kg) C — Culture-directed de-escalation + Corticosteroids (if refractory shock) D — Dynamic haemodynamic monitoring + De-resuscitation after stabilisation E — Early enteral nutrition + Early mobility + Elimination of source
References
- SSC 2026 Adult Guidelines — Evans L et al. Intensive Care Medicine / Critical Care Medicine, March 2026. SCCM Full Guideline
- SSC 2026 Paediatric Guidelines — Weiss SL et al. Pediatric Critical Care Medicine, April 2026. PMID: 41869844
- Miller's Anaesthesia 10e — Chapter 79 (Sepsis & Septic Shock)
- Schwartz's Principles of Surgery 11e — Chapter 6 (Table 6-10)
- Harrison's Principles of Internal Medicine 22e (2025)
- ESICM 2026 SSC Commentary
- EMCrit SSC 2026 Analysis
Exam Tip: The 2026 SSC guidelines contain 129 statements (46 new). The most commonly tested areas in MD Anaesthesiology are: Hour-1 bundle, vasopressor choice/timing, fluid type/volume, corticosteroid dosing, mechanical ventilation targets, and the reversal of the Vitamin C recommendation. Post-discharge PICS care is a new high-yield topic.
This is a shared conversation. Sign in to Orris to start your own chat.